Cargando…

PCSK9 Inhibition: Does Lipoprotein Size Matter?

Detalles Bibliográficos
Autores principales:	Si‐Tayeb, Karim, Cariou, Bertrand
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2015
Materias:	Editorials
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4845216/ https://www.ncbi.nlm.nih.gov/pubmed/26586733 http://dx.doi.org/10.1161/JAHA.115.002806

Ejemplares similares

Lipoprotein(a) and PCSK9 inhibition: clinical evidence
por: Ruscica, Massimiliano, et al.
Publicado: (2020)

LDL lowering effect of PCSK9 inhibition is reduced in women
por: Myasoedova, Veronika A, et al.
Publicado: (2023)

Urine-sample-derived human induced pluripotent stem cells as a model to study PCSK9-mediated autosomal dominant hypercholesterolemia
por: Si-Tayeb, Karim, et al.
Publicado: (2016)

PCSK9 regulates the NODAL signaling pathway and cellular proliferation in hiPSCs
por: Roudaut, Meryl, et al.
Publicado: (2021)

PCSK9 inhibition in high-risk patients
por: Zijlstra, Laurien E., et al.
Publicado: (2019)

Effects of PCSK9 Inhibition With Alirocumab on Lipoprotein Metabolism in Healthy Humans
por: Reyes-Soffer, Gissette, et al.
Publicado: (2017)

PCSK9 and triglyceride-rich lipoprotein metabolism
por: Druce, Irena, et al.
Publicado: (2015)

Low Density Lipoprotein Binds to Proprotein Convertase Subtilisin/Kexin Type-9 (PCSK9) in Human Plasma and Inhibits PCSK9-mediated Low Density Lipoprotein Receptor Degradation
por: Kosenko, Tanja, et al.
Publicado: (2013)

Relationship Between Low‐Density Lipoprotein Cholesterol and Lipoprotein(a) Lowering in Response to PCSK9 Inhibition With Evolocumab
por: Shapiro, Michael D., et al.
Publicado: (2019)

Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol
por: Schwartz, Gregory G., et al.
Publicado: (2021)

PCSK9: The Nexus of Lipoprotein Metabolism and Inflammation in COVID-19
por: Goonewardena, Sascha N., et al.
Publicado: (2023)

Effect of PCSK9 inhibition with evolocumab on lipoprotein subfractions in familial dysbetalipoproteinemia (type III hyperlipidemia)
por: Waldmann, Elisa, et al.
Publicado: (2022)

Orally Bioavailable Macrocyclic Peptide That Inhibits Binding of PCSK9 to the Low Density Lipoprotein Receptor
por: Johns, Douglas G., et al.
Publicado: (2023)

Inhibition of PCSK9 does not improve lipopolysaccharide-induced mortality in mice
por: Berger, Jean-Mathieu, et al.
Publicado: (2017)

Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Deletion but Not Inhibition of Extracellular PCSK9 Reduces Infarct Sizes Ex Vivo but Not In Vivo
por: Schreckenberg, Rolf, et al.
Publicado: (2022)

Effect of Evolocumab on Lipoprotein(a) and PCSK9 in Healthy Individuals with Elevated Lipoprotein(a) Level
por: Afanasieva, Olga, et al.
Publicado: (2020)

Targeting PCSK9 and Beyond for the Management of Low-Density Lipoprotein Cholesterol
por: Mohamed, Farzahna, et al.
Publicado: (2023)

Diabetes and pancreas size, does it matter?
por: Yagihashi, Soroku
Publicado: (2016)

Reduction of cerebrovascular and peripheral events with PCSK9 inhibitors: Does it just depend on the lowering of the low-density lipoprotein?
por: Cesaro, Arturo, et al.
Publicado: (2022)

Just Price for PCSK9 Inhibitors: No less, No More
por: Nasir, Khurram
Publicado: (2018)

Effect of PCSK9 Inhibition by Alirocumab on Lipoprotein Particle Concentrations Determined by Nuclear Magnetic Resonance Spectroscopy
por: Koren, Michael J., et al.
Publicado: (2015)

Effect of PCSK9 inhibitor on lipoprotein particles in patients with acute coronary syndromes
por: Li, Tingting, et al.
Publicado: (2021)

PCSK9 Inhibitors: What Lies Beyond Monoclonal Antibodies?
por: EBioMedicine
Publicado: (2015)

PCSK9 and carbohydrate metabolism: A double-edged sword
por: Filippatos, Theodosios D, et al.
Publicado: (2017)

Lipoprotein(a) Cellular Uptake Ex Vivo and Hepatic Capture In Vivo Is Insensitive to PCSK9 Inhibition With Alirocumab
por: Chemello, Kévin, et al.
Publicado: (2020)

PCSK9 is not secreted from mature differentiated intestinal cells
por: Moreau, François, et al.
Publicado: (2021)

Antibody-mediated disruption of the interaction between PCSK9 and the low-density lipoprotein receptor
por: Duff, Christopher J., et al.
Publicado: (2009)

The discovery of PCSK9 inhibitors: A tale of creativity and multifaceted translational research
por: Elguindy, Ahmed, et al.
Publicado: (2013)

Relation of plasma PCSK9 levels to lipoprotein subfractions in patients with stable coronary artery disease
por: Xu, Rui-Xia, et al.
Publicado: (2014)

Effect of a novel nutraceutical combination on serum lipoprotein functional profile and circulating PCSK9
por: Adorni, Maria Pia, et al.
Publicado: (2017)

Use of Low‐Density Lipoprotein–Lowering Therapies Before and After PCSK9 Inhibitor Initiation
por: Rymer, Jennifer A., et al.
Publicado: (2020)

Interplay between microRNAs, Serum Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9), and Lipid Parameters in Patients with Very High Lipoprotein(a) Treated with PCSK9 Inhibitors
por: Levstek, Tina, et al.
Publicado: (2023)

PCSK9 inhibition: the way forward in the treatment of dyslipidemia
por: Stoekenbroek, Robert M., et al.
Publicado: (2015)

PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab
por: Blom, Dirk J, et al.
Publicado: (2016)

Role of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) on Lipid Metabolism and Insulin Resistance in Human
por: Muraki, Isao
Publicado: (2021)

Challenges with PCSK9 Inhibitors Use in Asia Given Real-World Data Implications
por: Uno-Eder, Kiyoko
Publicado: (2023)

PCSK9 and Calcific Aortic Valve Stenosis: Moving Beyond Lipids
por: Leopold, Jane A.
Publicado: (2020)

HIV and Hepatitis C–Coinfected Patients Have Lower Low‐Density Lipoprotein Cholesterol Despite Higher Proprotein Convertase Subtilisin Kexin 9 (PCSK9): An Apparent “PCSK9–Lipid Paradox”
por: Kohli, Payal, et al.
Publicado: (2016)

SUN-580 PCSK9 and Lp(a): Association Between PCSK9 Level and Larger Apo(a) Isoform Size in African-Americans and Caucasians
por: Byambaa, Enkhmaa, et al.
Publicado: (2020)

PCSK9 Modulates the Secretion But Not the Cellular Uptake of Lipoprotein(a) Ex Vivo: An Effect Blunted by Alirocumab
por: Villard, Elise F., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_l3lo5r5phtd0af786i506ghpr8